Deal facts
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Silence Therapeutics plc
- Deal value
- Not disclosed
- Announced
- 18 October 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United Kingdom
- Consideration
- cash
Sources
Merck KGaA, based in Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc in a cash deal that will take the healthcare company private. The transaction, announced on 18 October 2026, involves the German pharmaceutical group purchasing the British biotechnology firm. While the specific financial terms and total offer value have not been publicly reported, the consideration is structured entirely in cash. This move represents a significant shift for Silence Therapeutics, which will transition from a publicly listed entity to a privately held company under the ownership of Merck. The deal highlights the continued interest of major pharmaceutical players in acquiring assets within the healthcare sector, specifically focusing on companies with established research portfolios. By removing the target from public markets, the buyer aims to integrate the business without the pressures of quarterly reporting. The acquisition underscores the strategic importance of Silence Therapeutics within the broader industry landscape. As the process moves forward, the transaction remains at the firm intention stage. The completion of the deal is subject to necessary regulatory approvals and other customary closing conditions.
Deal timeline
1 update- Firm intention
Merck KGaA, Darmstadt, Germany firm intention to acquire Silence Therapeutics plc
Item 1.01 Entry into a Material Definitive Agreement. Transaction Agreement On October 18, 2026, Silence Therapeutics plc, a public limited company incorporated in England and Wales (the “ Company ”), entered into a transaction agreement (the “ Transaction Agreement ”) with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“ Purchaser ”). The Transaction Agreement provide
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Merck KGaA, Darmstadt, Germany to acquire Rapid Micro Biosystems, Inc.
Merck KGaA, Darmstadt, Germany has agreed to acquire Rapid Micro Biosystems, Inc. (Nasdaq: RPID) for cash. The Agreement and Plan of Merger was signed on November 16, 20…
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Rapid Micro Biosystems, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Rosemont Pharmaceuticals Holdings, Inc. to acquire Aytu BioPharma Inc.
Aytu BioPharma Inc., a Nasdaq-listed Delaware company, agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings, Inc. The two signed an Agreement…
- Buyer
- Rosemont Pharmaceuticals Holdings, Inc.
- Target
- Aytu BioPharma Inc.
- Deal value
- Not disclosed
- Deal type
- going private
ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.
ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…
- Buyer
- ArcheNova Technology Co., Ltd
- Target
- ArcheNova Biotech Corp.
- Deal value
- USD 2,000,000,000
- Deal type
- going private
Onyx Bidco LLC to acquire Option Care Health, Inc.
Option Care Health, Inc. entered into an Agreement and Plan of Merger on October 5, 2026 with Onyx Bidco LLC and its wholly owned subsidiary Onyx Merger Sub, Inc., both…
- Buyer
- Onyx Bidco LLC
- Target
- Option Care Health, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Lifecore Inc. to acquire Lifecore Biomedical, Inc.
Lifecore Inc. and Lifecore Biomedical, Inc. entered the Exit Mode archive.
- Buyer
- Lifecore Inc.
- Target
- Lifecore Biomedical, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Merck KGaA, Darmstadt, Germany
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive